Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gontivimab for RSV in HSCT Recipients
NCT03468829Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- Feb 2019
- Primary completion
- May 2020
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of gontivimab in respiratory syncytial virus infection (RSV), sponsored by Sanofi. Planned start Feb 2019; status: withdrawn.
02
Drugs
gontivimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03468829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468829.